Status:
UNKNOWN
Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer
Lead Sponsor:
Qilu Hospital of Shandong University
Collaborating Sponsors:
Jiangsu HengRui Medicine Co., Ltd.
Conditions:
Small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This is a Phase II, Open, Single-center Study of Camrelizumab and Fluzoparib as Consolidation Treatment for Patients With Extensive stage small cell lung cancer Who Have Not Progressed after first-lin...
Eligibility Criteria
Inclusion
- All subjects were required to sign the informed consent before starting the study;
- Histologically documented Extensive stage small cell lung cancer；
- ECOG PS 0\~1 ；
- 18-75 years；
- According to recist1.1, CR or PR was achieved after 4-6 cycles of first-line etoposide and platinum chemotherapy;
- .Life expectancy ≥ 3 months；
Exclusion
- Recurrence or distant metastasis of localized small cell lung cancer after chemotherapy or concurrent chemoradiotherapy；
- Active infection including tuberculosis, HIV, hepatitis B and C；
- Interstitial pneumonia (ILD), drug-induced pneumonia, radiation-induced pneumonia requiring steroid therapy or active pneumonia with clinical symptoms, or other moderate to severe lung diseases that seriously affect lung function;
- Severe infection existed, including but not limited to infection complications, bacteremia, severe pneumonia, etc;
- Symptomatic brain metastasis and cancerous meningitis;
Key Trial Info
Start Date :
May 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04782089
Start Date
May 6 2021
End Date
June 1 2024
Last Update
March 4 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.